Literature DB >> 12830009

The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club.

Kevin P Moore1, Florence Wong, Pere Gines, Mauro Bernardi, Andreas Ochs, Francesco Salerno, Paolo Angeli, Michael Porayko, Richard Moreau, Guadelupe Garcia-Tsao, Wladimiro Jimenez, Ramon Planas, Vicente Arroyo.   

Abstract

Ascites is a common complication of cirrhosis, and heralds a new phase of hepatic decompensation in the progression of the cirrhotic process. The development of ascites carries a significant worsening of the prognosis. It is important to diagnose noncirrhotic causes of ascites such as malignancy, tuberculosis, and pancreatic ascites since these occur with increased frequency in patients with liver disease. The International Ascites Club, representing the spectrum of clinical practice from North America to Europe, have developed guidelines by consensus in the management of cirrhotic ascites from the early ascitic stage to the stage of refractory ascites. Mild to moderate ascites should be managed by modest salt restriction and diuretic therapy with spironolactone or an equivalent in the first instance. Diuretics should be added in a stepwise fashion while maintaining sodium restriction. Gross ascites should be treated with therapeutic paracentesis followed by colloid volume expansion, and diuretic therapy. Refractory ascites is managed by repeated large volume paracentesis or insertion of a transjugular intrahepatic portosystemic stent shunt (TIPS). Successful placement of TIPS results in improved renal function, sodium excretion, and general well-being of the patient but without proven survival benefits. Clinicians caring for these patients should be aware of the potential complications of each treatment modality and be prepared to discontinue diuretics or not proceed with TIPS placement should complications or contraindications develop. Liver transplantation should be considered for all ascitic patients, and this should preferably be performed prior to the development of renal dysfunction to prevent further compromise of their prognosis.

Entities:  

Mesh:

Year:  2003        PMID: 12830009     DOI: 10.1053/jhep.2003.50315

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  194 in total

1.  Transjugular intrahepatic portosystemic shunt for portal cavernoma with symptomatic portal hypertension in non-cirrhotic patients.

Authors:  Xingshun Qi; Guohong Han; Zhanxin Yin; Chuangye He; Jianhong Wang; Wengang Guo; Jing Niu; Wei Zhang; Ming Bai; Daiming Fan
Journal:  Dig Dis Sci       Date:  2011-12-07       Impact factor: 3.199

2.  TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial.

Authors:  Alexander S Rosemurgy; Emmanuel E Zervos; Whalen C Clark; Donald P Thometz; Thomas J Black; Bruce R Zwiebel; Bruce T Kudryk; L Shane Grundy; Larry C Carey
Journal:  Ann Surg       Date:  2004-06       Impact factor: 12.969

3.  Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension.

Authors:  Mubin I Syed; Hetal Karsan; Hector Ferral; Azim Shaikh; Uzma Waheed; Talal Akhter; Alan Gabbard; Kamal Morar; Robert Tyrrell
Journal:  World J Hepatol       Date:  2012-02-27

4.  Ascites symptom inventory-7 is a valuable tool for evaluating the effectiveness of tolvaptan in patients with cirrhotic ascites.

Authors:  Hideto Kawaratani; Kei Moriya; Tadashi Namisaki; Naotaka Shimozato; Kosuke Kaji; Hiroaki Takaya; Yukihisa Fujinaga; Yasuhiko Sawada; Shinya Sato; Soichiro Saikawa; Takuya Kubo; Takemi Akahane; Hiroshi Fukui; Hitoshi Yoshiji
Journal:  Exp Ther Med       Date:  2020-11-10       Impact factor: 2.447

Review 5.  Treatment and management of ascites and hepatorenal syndrome: an update.

Authors:  Kurt Lenz; Robert Buder; Lisbeth Kapun; Martin Voglmayr
Journal:  Therap Adv Gastroenterol       Date:  2015-03       Impact factor: 4.409

6.  Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites.

Authors:  G Nasr; A Hassan; S Ahmed; A Serwah
Journal:  J Cardiovasc Dis Res       Date:  2010-07

Review 7.  Current management of the complications of portal hypertension: variceal bleeding and ascites.

Authors:  Nina Dib; Frédéric Oberti; Paul Calès
Journal:  CMAJ       Date:  2006-05-09       Impact factor: 8.262

8.  Addition of adult-to-adult living donation to liver transplant programs improves survival but at an increased cost.

Authors:  Patrick G Northup; Michael M Abecassis; Michael J Englesbe; Jean C Emond; Vanessa D Lee; George J Stukenborg; Lan Tong; Carl L Berg
Journal:  Liver Transpl       Date:  2009-02       Impact factor: 5.799

9.  Urine albumin-to-creatinine ratio is associated with the severity of liver disease, renal function and survival in patients with decompensated cirrhosis.

Authors:  Evangelos Cholongitas; Ioannis Goulis; Maria Ioannidou; Stergios Soulaidopoulos; Parthenis Chalevas; Evangelos Akriviadis
Journal:  Hepatol Int       Date:  2016-08-30       Impact factor: 6.047

10.  Spontaneous Umbilical Hernia Rupture Associated With Omentum Evisceration in a Patient With Advanced Hepatic Cirrhosis and Refractory Ascites.

Authors:  Abdulqader M Albeladi; Ahmad M Odeh; Aminah H AlAli; Abdullah M Alkhars; Adeeb M Buhlaigah; Hussain A Alghadeer; Mohammed J Almosbeh; Mohmmed T AlAbbad; Mohammad S AlGhadeer
Journal:  Cureus       Date:  2021-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.